A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Investegate |Evgen Pharma PLC Announcements | Evgen Pharma PLC: Director dealing investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
17 February 2021 | 09:28am
StockMarketWire.com - Drug development company Evgen Pharma said it expected to complete recruitment for the trial of its SFX-01 drug candidate to treat acute respiratory infections in patients with suspected Covid-19, by the end of 2021 or the first quarter of 2022.
As of 16 February, a total of 102 patients had been recruited and randomised to the trial, the company said.
Initial data from the assessment of the safety and futility of the trial was expected in the second quarter of calendar 2021.
Story provided by StockMarketWire.com
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.